LIXTE Biotechnology's LB100 Clinical Trials Receive Support from New Scientific Findings in Nature

LIXTE Biotechnology's LB100 drug, being tested for ovarian and colorectal cancers, has been supported by new scientific findings published in Nature. A study led by Professor Amir Jazaeri from The University of Texas MD Anderson Cancer Center found that patients with tumors exhibiting inactivating mutations in the PPP2R1A gene showed better survival outcomes. These mutations are targeted by LB100, which is currently being tested in combination with checkpoint immunotherapy in two clinical trials.

Title: New Scientific Findings Support LIXTE Biotechnology's LB100 in Ovarian and Colorectal Cancer Trials

Pasadena, Calif., July 2, 2025 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company, has received significant support for its LB100 drug through new scientific findings published in Nature. The study, led by Professor Amir Jazaeri from The University of Texas MD Anderson Cancer Center, validates LIXTE’s ongoing clinical trials with LB100 for ovarian and colorectal cancers [1].

The Nature article indicates that inhibition of PP2A enhances immunotherapy response with LIXTE’s proprietary compound LB100. A team of physician-scientists studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint blockade therapy. The study found that patients with tumors exhibiting inactivating mutations in PPP2R1A had significantly better overall survival compared to those without such mutations [1].

These inactivating mutations in PPP2R1A reduce the enzymatic activity of PP2A, which is the target of LIXTE’s lead compound LB-100. Tumors with mutations in PPP2R1A were found to have increased the interferon gamma response pathway, which is associated with improved immune checkpoint responses. This finding aligns with LIXTE’s clinical trials, which are currently investigating the activity of LB-100 in combination with checkpoint immunotherapy [1].

LIXTE is currently conducting two clinical trials involving LB-100. The first trial, enrolling patients with OCCC, is led by Dr. Jazaeri at MD Anderson Cancer Center and is also open at Northwestern University. This trial is in collaboration with GSK to test LB-100 in combination with dostarlimab (anti PD1). The second trial at the Netherlands Cancer Institute is in collaboration with Roche to test LB-100 in combination with atezolizumab (anti PDL1) in colon cancer patients [1].

“Not only did we identify a new biomarker for improved survival with immunotherapy in ovarian cancer, but we also confirmed the correlation of this biomarker with survival benefit in other cancer types,” said Dr. Jazaeri, co-senior author of the Nature article. “Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway using drugs, which we currently are evaluating in a clinical trial at MD Anderson” [1].

Bas van der Baan, LIXTE’s Chief Scientific Officer, added, “This work extends a body of pre-clinical evidence indicating that LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our clinical studies in the second half of this year” [1].

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [1].

References:

[1] https://www.biospace.com/press-releases/new-clinical-findings-published-in-scientific-journal-nature-validate-lixtes-ongoing-ovarian-and-colorectal-cancer-trials